Abstract
We demonstrate that a Bayesian approach (the use of prior knowledge) to the design of steady-state experiments can produce major gains quantifiable in terms of information, productivity and accuracy of each experiment. Developing the use of Bayesian utility functions, we have used a systematic method to identify the optimum experimental designs for a number of kinetic model data sets. This has enabled the identification of trends between kinetic model types, sets of design rules and the key conclusion that such designs should be based on some prior knowledge of the kinetic model. We suggest an optimal and iterative method for selecting features of the design such as the substrate range, number of measurements and choice of intermediate points. The final design collects data suitable for accurate modelling and analysis and minimises the error in the parameters estimated. It is equally applicable to enzymes, drug transport, receptor binding, microbial culture and cell transport kinetics.
Keywords: kinetics, experimental design, bayesian design, kinetic parameters, prior knowledge, parameter variance, drug discovery
Medicinal Chemistry
Title: Novel Experimental Design for Steady-state Processes: A Systematic Bayesian Approach for Enzymes, Drug Transport, Receptor Binding, Continuous Culture and Cell Transport Kinetics
Volume: 1 Issue: 1
Author(s): M. James C. Crabbe, Emma F. Murphy and Steven G. Gilmour
Affiliation:
Keywords: kinetics, experimental design, bayesian design, kinetic parameters, prior knowledge, parameter variance, drug discovery
Abstract: We demonstrate that a Bayesian approach (the use of prior knowledge) to the design of steady-state experiments can produce major gains quantifiable in terms of information, productivity and accuracy of each experiment. Developing the use of Bayesian utility functions, we have used a systematic method to identify the optimum experimental designs for a number of kinetic model data sets. This has enabled the identification of trends between kinetic model types, sets of design rules and the key conclusion that such designs should be based on some prior knowledge of the kinetic model. We suggest an optimal and iterative method for selecting features of the design such as the substrate range, number of measurements and choice of intermediate points. The final design collects data suitable for accurate modelling and analysis and minimises the error in the parameters estimated. It is equally applicable to enzymes, drug transport, receptor binding, microbial culture and cell transport kinetics.
Export Options
About this article
Cite this article as:
Crabbe C. M. James, Murphy F. Emma and Gilmour G. Steven, Novel Experimental Design for Steady-state Processes: A Systematic Bayesian Approach for Enzymes, Drug Transport, Receptor Binding, Continuous Culture and Cell Transport Kinetics, Medicinal Chemistry 2005; 1 (1) . https://dx.doi.org/10.2174/1573406053402550
DOI https://dx.doi.org/10.2174/1573406053402550 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorescein-labeled Bacitracin and Daptomycin Conjugates: Synthesis, Fluorescence Imaging and Evaluation
Medicinal Chemistry Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells
Current Radiopharmaceuticals Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Current Medicinal Chemistry Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics
Current Drug Metabolism Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Targeted Ultrasound Imaging of Cancer: An Emerging Technology on its Way to Clinics
Current Pharmaceutical Design Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Current Drug Abuse Reviews LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy Development of Selective High Affinity Antagonists, Agonists, and Radioligands for the P2Y1 Receptor
Combinatorial Chemistry & High Throughput Screening Detection of Unilateral Hearing Loss by Stationary Wavelet Entropy
CNS & Neurological Disorders - Drug Targets Recent Advances in the Mitsunobu Reaction: Modifications and Applications to Biologically Active Molecules
Current Organic Chemistry